CRISPR technology is transforming modern medicine by enabling precise DNA editing to treat genetic disorders, including sickle cell anemia and beta-thalassemia, experts say.

CRISPR is revolutionizing medicine by enabling precise DNA edits, treating genetic diseases like sickle cell anemia and ...

Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) has continued to show benefits in sickle cell disease (SCD) ...

Vertex Pharmaceuticals unveiled impressive long-term results for its CRISPR/Cas9 gene therapy, PrCASGEVY, at the EHA Congress ...

Editas Medicine, Inc. (NASDAQ:EDIT) ranks among the best CRISPR stocks to buy. At the European Hematology Association 2025 ...

Hemoglobinopathies Market The hemoglobinopathies market is advancing rapidly, driven by gene therapy, new drugs, and rising access for trea ...

Genetics plays a crucial role in reproductive medicine, impacting both fertility and the health of offspring. According to ...

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

Genetic disease impacts millions of children in the U.S., with Down syndrome, cystic fibrosis, Tay-Sachs disease and sickle ...

Editas Medicine reports successful gene editing levels in stem cells, supporting potential treatment for sickle cell disease and beta thalassemia.

Thalassemia in India: A Public Health Concern India is home to over 100,000 individuals with thalassemia major, and an estimated 35 to 40 million carriers of the beta thalassemia gene, according ...

You’ve likely heard people mention that they have inherited certain health conditions from their family. These are known as ...